Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsA.S. and D.H. declare employment at LamKap Bio Group. S.M., V.M., L.N., B.D., U.R., N.P., S.C., L.B., L.C., A.L., L.Ch., A.P., K.M., Y.P., G.M., P.M., and L.S. declare employment at Light Chain Bioscience—Novimmune SA. S.S.P. declares consultancy work for Light Chain Bioscience—Novimmune SA and LamKap Bio. A.S., K.S., and D.H. hold shares of LamKap Bio. S.K. declares research funding from LamKap Bio. S.Kr. received fees for lectures of MSD Sharp & Dohme GmbH and collaborates with Johnson&Johnson GmbH. F.L. received fees for lectures, expert appraisal or consulting services from Amgen GmbH, Astellas Pharma GmbH, AstraZeneca GmbH, Bayer AG, BioNTech SE, Bristol-Myers Squibb GmbH & Co. KGaA, Daiichi Sankyo Deutschland GmbH, Lilly Deutschland GmbH, Elsevier GmbH, Falk Foundation e.V., Incyte Inc, Merck KGaA, MSD Sharp & Dohme GmbH, Novartis Pharma GmbH, Roche Deutschland Holding GmbH, Servier Deutschland GmbH, Springe Nature AG & Co. KGaA, StreamedUp! GmbH; research projects are supported by Bristol-Myers Squibb GmbH und Co. KGaA and Gilead Science GmbH. H.N. and I.G. declare no potential conflicts of interest. Competing interests A.S. and D.H. declare employment at LamKap Bio Group. S.M., V.M., L.N., B.D., U.R., N.P., S.C., L.B., L.C., A.L., L.Ch., A.P., K.M., Y.P., G.M., P.M., and L.S. declare employment at Light Chain Bioscience—Novimmune SA. S.S.P. declares consultancy work for Light Chain Bioscience—Novimmune SA and LamKap Bio. A.S., K.S., and D.H. hold shares of LamKap Bio. S.K. declares research funding from LamKap Bio. S.Kr. received fees for lectures of MSD Sharp & Dohme GmbH and collaborates with Johnson&Johnson GmbH. F.L. received fees for lectures, expert appraisal or consulting services from Amgen GmbH, Astellas Pharma GmbH, AstraZeneca GmbH, Bayer AG, BioNTech SE, Bristol-Myers Squibb GmbH & Co. KGaA, Daiichi Sankyo Deutschland GmbH, Lilly Deutschland GmbH, Elsevier GmbH, Falk Foundation e.V., Incyte Inc, Merck KGaA, MSD Sharp & Dohme GmbH, Novartis Pharma GmbH, Roche Deutschland Holding GmbH, Servier Deutschland GmbH, Springe Nature AG & Co. KGaA, StreamedUp! GmbH; research projects are supported by Bristol-Myers Squibb GmbH und Co. KGaA and Gilead Science GmbH. H.N. and I.G. declare no potential conflicts of interest."

"Funding The study was funded by LamKap Bio alpha."